Furthermore, we aimed to investigate mechanisms by which lncRNA contributes to tamoxifen resistance and to identify novel therapeutic targets within CAF-derived exosomal lncRNAs to overcome tamoxifen resistance in ER + breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.